ProKidney Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

ProKidneyDer Gewinn des Unternehmens wird voraussichtlich um 10.7% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 84.8% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich sinken um 4.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -47.1% betragen.

Wichtige Informationen

-10.7%

Wachstumsrate der Gewinne

-4.2%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	84.8%
Zukünftige Eigenkapitalrendite	-47.1%
Analystenabdeckung	Low
Zuletzt aktualisiert	21 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Here's Why We're Not Too Worried About ProKidney's (NASDAQ:PROK) Cash Burn Situation

Nov 17

ProKidney (NASDAQ:PROK) Is In A Strong Position To Grow Its Business

Mar 14

ProKidney reports Q2 2022 results

Aug 11

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:PROK - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-107	-216	-160	2
12/31/2025	N/A	-73	-167	-136	3
12/31/2024	N/A	-58	-145	-92	3
9/30/2024	N/A	-46	-133	-128	N/A
6/30/2024	N/A	-39	-153	-122	N/A
3/31/2024	N/A	-35	-133	-99	N/A
12/31/2023	N/A	-35	-124	-90	N/A
9/30/2023	N/A	-36	-113	-80	N/A
6/30/2023	N/A	-33	-85	-80	N/A
3/31/2023	N/A	43	-90	-88	N/A
12/31/2022	N/A	-14	-79	-77	N/A
9/30/2022	N/A	-22	-76	-74	N/A
6/30/2022	N/A	-31	-73	-70	N/A
3/31/2022	N/A	-111	-63	-59	N/A
12/31/2021	N/A	-55	-55	-50	N/A
9/30/2021	N/A	-49	-52	-45	N/A
12/31/2020	N/A	-27	-31	-25	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: PROK wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: PROK wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: PROK wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: PROK wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: PROK wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: PROK wird voraussichtlich in 3 Jahren unrentabel sein.

ProKidney Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 24% to US$4.83

Price target decreased by 19% to US$12.50

Recent updates

We're Hopeful That ProKidney (NASDAQ:PROK) Will Use Its Cash Wisely

Prokidney Corp. Reports Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

Prokidney Announces Strategic Updates to Its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S

New minor risk - Shareholder dilution

We're Not Very Worried About ProKidney's (NASDAQ:PROK) Cash Burn Rate

New minor risk - Shareholder dilution

ProKidney Corp. has completed a Follow-on Equity Offering in the amount of $26.693989 million.

New minor risk - Shareholder dilution

ProKidney Corp. Announces Positive Interim Regen-007 Phase 2 Trial Data and Provides Clinical and Operational Updates

Price target decreased by 24% to US$4.83

Chief Reg. Off notifies of intention to sell stock

We Think ProKidney (NASDAQ:PROK) Can Afford To Drive Business Growth

ProKidney Corp., Annual General Meeting, May 30, 2024

New major risk - Share price stability

Chief Reg. Off notifies of intention to sell stock

ProKidney Corp. Announces Key Leadership Appointments Strengthening Clinical and Technical Operations

New major risk - Revenue and earnings growth

New minor risk - Market cap size

ProKidney Corp. Announces Termination of Deepak Jain as Chief Operating Officer

Prokidney Appoints Nikhil Pereira-Kamath as Chief Business Officer

ProKidney Corp. (NasdaqCM:PROK) announces an Equity Buyback for 7,256,367 shares, for $9.5 million.

New major risk - Revenue and earnings growth

Here's Why We're Not Too Worried About ProKidney's (NASDAQ:PROK) Cash Burn Situation

Price target decreased by 19% to US$12.50

ProKidney Corp. Announces Executive Changes

ProKidney Corp. Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD

Investor sentiment deteriorates as stock falls 17%

Investor sentiment deteriorates as stock falls 22%

Investor sentiment deteriorates as stock falls 20%

Investor sentiment deteriorates as stock falls 20%

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

ProKidney Corp. Announces the Appointment of Bruce Culleton, MD, as Executive Vice President, Clinical Development and Commercialization

Now 24% undervalued

Investor sentiment improves as stock rises 15%

ProKidney Corp., Annual General Meeting, Jun 29, 2023

Investor sentiment improves as stock rises 19%

ProKidney (NASDAQ:PROK) Is In A Strong Position To Grow Its Business

Libbie McKenzie Resigns from Prokidney as Chief Medical Officer

ProKidney Announces Publication of Trial Design for Phase 2 Multicenter Clinical Trial of React for Late Stage 4 Diabetes-Related Chronic Kidney Disease

High number of new directors

ProKidney Corp. Appoints Glenn Schulman as Senior Vice President of Investor Relations

ProKidney Corp. Announces Board Appointments

ProKidney reports Q2 2022 results

ProKidney Corp. Appoints Kerry Cooper as Senior Vice President of Medical Affairs

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken